Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100PLL7
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥7.8bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥4.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥4.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥3.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥51.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥28.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥26.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥25.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.2bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.2bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.6bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.252021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.132021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.122021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio89.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 13
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 629
ItemContextValueUnit
Profit loss before tax IFRSPrior1QuarterDuration3529080000JPY
Profit loss before tax IFRSCurrentQuarterDuration1222472000JPY
Income tax expense IFRSPrior1QuarterDuration1044941000JPY
Income tax expense IFRSCurrentQuarterDuration276824000JPY
Profit loss IFRSPrior1QuarterDuration2484139000JPY
Profit loss IFRSCurrentQuarterDuration945647000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration2484139000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration945647000JPY
Profit loss IFRSPrior1QuarterDuration2484139000JPY
Profit loss IFRSCurrentQuarterDuration945647000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration19.13
Basic earnings loss per share IFRSCurrentQuarterDuration7.28
Diluted earnings loss per share IFRSPrior1QuarterDuration19.12
Diluted earnings loss per share IFRSCurrentQuarterDuration7.28
Profit loss IFRSPrior1YTDDuration2475803000JPY
Profit loss IFRSCurrentYTDDuration-186603000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration939358000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-709440000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration939358000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-709440000JPY
Other comprehensive income IFRSPrior1YTDDuration939358000JPY
Other comprehensive income IFRSCurrentYTDDuration-709440000JPY
Comprehensive income IFRSPrior1YTDDuration3415162000JPY
Comprehensive income IFRSCurrentYTDDuration-896044000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration3415162000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration-896044000JPY
Comprehensive income IFRSPrior1YTDDuration3415162000JPY
Comprehensive income IFRSCurrentYTDDuration-896044000JPY
Profit loss IFRSPrior1QuarterDuration2484139000JPY
Profit loss IFRSCurrentQuarterDuration945647000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration55207000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-1142611000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration55207000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-1142611000JPY
Other comprehensive income IFRSPrior1QuarterDuration55207000JPY
Other comprehensive income IFRSCurrentQuarterDuration-1142611000JPY
Comprehensive income IFRSPrior1QuarterDuration2539346000JPY
Comprehensive income IFRSCurrentQuarterDuration-196963000JPY
Comprehensive income attributable to owners of parent IFRSPrior1QuarterDuration2539346000JPY
Comprehensive income attributable to owners of parent IFRSCurrentQuarterDuration-196963000JPY
Comprehensive income IFRSPrior1QuarterDuration2539346000JPY
Comprehensive income IFRSCurrentQuarterDuration-196963000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember3933885000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember10305306000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-655383000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember7503531000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember191468000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember21278808000JPY
Equity IFRSPrior2YearInstant21278808000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass